使用无进展生存期比值比较神经内分泌肿瘤的治疗表现与治疗顺序
这项回顾性研究纳入维也纳医科大学2010—2024年治疗的177例转移性神经内分泌肿瘤患者,采用无进展生存期比值(PFS比值)比较不同治疗顺序的相对获益。一线SSA后序贯PRRT的中位PFS比值为1.86,依维莫司为0.99,其他治疗为0.59(p=0.004)。作者认为PFS比值可适应NEN异质性,为治疗表现与顺序提供见解。
要点
- 一线SSA后序贯PRRT的中位PFS比值为1.86,依维莫司为0.99,其他治疗为0.59(p=0.004)。
- 铂类/依托泊苷后FOLFOX/FOLFIRI的中位PFS比值为0.46。
- 亚组分析中,肺/胸腺类癌在SSA/PRRT后使用依维莫司呈现不成比例延长的PFS间期。
核心结论
- PFS比值可适应NEN的异质性,并能提供关于治疗表现和治疗顺序的见解。
研究设计与样本
- 回顾性研究纳入维也纳医科大学2010—2024年治疗的转移性神经内分泌肿瘤患者,要求接受过至少2种姑息性全身治疗,共177例。
- PFS比值定义为后续治疗PFS2与先前治疗PFS1之比。
主要发现
- 177例中,104例为NET G1/G2,16例为NET G3,28例为肺/胸腺类癌,29例为神经内分泌癌(NEC)。
- NET G1/G2和胸部类癌中最常见的一线治疗为SSA(n=84),其后常序贯PRRT(n=60)、依维莫司(n=13)和归为「其他」的治疗(n=9)。
- NEC中铂类/依托泊苷(n=26)后,二线治疗为FOLFOX/FOLFIRI(n=13)、CAPTEM(n=3)和「其他」治疗(n=9)。
- 一线SSA后序贯PRRT的中位PFS比值为1.86,依维莫司为0.99,「其他」治疗为0.59(p=0.004)。
- 铂类/依托泊苷后FOLFOX/FOLFIRI的中位PFS比值为0.46;按原发部位亚组分析中,肺/胸腺类癌在SSA/PRRT后使用依维莫司呈现不成比例延长的PFS间期,而肠胰NET中PRRT后治疗的PFS比值相对较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Optimal sequencing of therapies is an important unresolved issue in metastatic neuroendocrine neoplasms (NEN). Progression-free survival (PFS) ratios constitute a potential method for intra-patient treatment comparisons and were used in this analysis to assess the relative treatment benefit of established therapies. METHODS: This retrospective study included NEN patients of the Medical University of Vienna (treated in 2010-2024) who had metastatic disease and had received ≥ 2 palliative systemic therapies. The primary objective was the calculation of PFS ratios for therapy sequences, with the PFS ratio defined as the proportion of PFS2 (subsequent treatment) and PFS1 (prior treatment). RESULTS: Of the 177 patients included, 104 had neuroendocrine tumors (NET) G1/G2, 16 NET G3, 28 lung/thymic carcinoids, and 29 a neuroendocrine carcinoma (NEC). In terms of treatment sequence, SSA was the most common first-line treatment in NET G1/G2 and thoracic carcinoids (n = 84), frequently followed by PRRT (n = 60), everolimus (n = 13), and treatments grouped as 'other' (n = 9). After platinum/etoposide in NEC (n = 26), FOLFOX/FOLFIRI (n = 13), CAPTEM (n = 3), and 'other' therapies (n = 9) were second-line therapies. The median PFS ratio for PRRT after first-line SSA was 1.86, for everolimus 0.99, and for 'other' treatments 0.59 (p = 0.004). Following platinum/etoposide, FOLFOX/FOLFIRI had a median PFS ratio of 0.46. In subgroup analyses according to primary localization, everolimus led to disproportionately long PFS intervals following SSA/PRRT in lung/thymic carcinoids, whereas therapies after PRRT exhibited relatively low PFS ratios in enteropancreatic NET. CONCLUSIONS: PFS ratios accommodate the heterogeneity of NEN and can provide insights regarding treatment performance and treatment sequencing.
引用
- Melhorn P, Kretschmer-Chott E, Mazal P, et al. Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios. Eur J Nucl Med Mol Imaging. 2025. PMID: 40542150. doi:10.1007/s00259-025-07411-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。